T Agizew1, R Boyd2, A F Auld3, L Payton4, S L Pals3, P Lekone4, V Chihota5, A Finlay2. 1. Centers for Disease Control and Prevention (CDC), Gaborone, Botswana, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, Faculty of Medicine, University of Botswana, Gaborone, Botswana. 2. Centers for Disease Control and Prevention (CDC), Gaborone, Botswana, Division of Tuberculosis Elimination. 3. Division of Global HIV and Tuberculosis, CDC, Atlanta, Georgia, USA. 4. Centers for Disease Control and Prevention (CDC), Gaborone, Botswana. 5. Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, Aurum Institute, Johannesburg, South Africa.
Abstract
BACKGROUND: Compared with smear microscopy, Xpert® MTB/RIF has the potential to reduce delays in tuberculosis (TB) diagnosis and treatment initiation, and improve treatment outcomes. We reviewed publications comparing treatment outcomes of drug-susceptible TB patients diagnosed using Xpert vs. smear. METHODS: Citations (2000-2016) reporting treatment outcomes of patients diagnosed using Xpert compared with smear were selected from PubMed, Scopus and conference abstracts. We conducted a systematic review and meta-analysis. Favorable (cured, completed) and unfavorable (failure, death, loss to follow-up) outcomes were pooled for meta-analysis; we also reviewed the number of TB cases diagnosed, time to treatment and empiric treatment. The Mantel-Haenszel method with a fixed-effect model was used; I² was calculated to measure heterogeneity. RESULTS: From 13 citations, 43 594 TB patients were included and 4825 were with known TB treatment outcome. From the pooled analysis, an unfavorable outcomes among those diagnosed using Xpert compared with smear was 20.2%, 541/2675 vs. 21.9%, 470/2150 (risk ratio 0.92, 95%CI 0.82-1.02). Statistical heterogeneity was low (I² = 0.0%, P = 0.910). Compared with smear, Xpert was reported to be superior in increasing the number of TB patients diagnosed (2/9 citations), increasing bacteriologically confirmed TB (7/9 citations), reducing empiric treatment (3/5 citations), reducing time to diagnosis (2/3 citations), and reducing time to treatment initiation (1/5 citations). CONCLUSIONS: Xpert implementation showed no discernible impact on treatment outcomes compared with conventional smear despite reduced time to diagnosis, time to treatment or reduced level of empiric treatment. Further research is required to learn more about gaps in the existing health system.
BACKGROUND: Compared with smear microscopy, Xpert® MTB/RIF has the potential to reduce delays in tuberculosis (TB) diagnosis and treatment initiation, and improve treatment outcomes. We reviewed publications comparing treatment outcomes of drug-susceptible TBpatients diagnosed using Xpert vs. smear. METHODS: Citations (2000-2016) reporting treatment outcomes of patients diagnosed using Xpert compared with smear were selected from PubMed, Scopus and conference abstracts. We conducted a systematic review and meta-analysis. Favorable (cured, completed) and unfavorable (failure, death, loss to follow-up) outcomes were pooled for meta-analysis; we also reviewed the number of TB cases diagnosed, time to treatment and empiric treatment. The Mantel-Haenszel method with a fixed-effect model was used; I² was calculated to measure heterogeneity. RESULTS: From 13 citations, 43 594 TBpatients were included and 4825 were with known TB treatment outcome. From the pooled analysis, an unfavorable outcomes among those diagnosed using Xpert compared with smear was 20.2%, 541/2675 vs. 21.9%, 470/2150 (risk ratio 0.92, 95%CI 0.82-1.02). Statistical heterogeneity was low (I² = 0.0%, P = 0.910). Compared with smear, Xpert was reported to be superior in increasing the number of TBpatients diagnosed (2/9 citations), increasing bacteriologically confirmed TB (7/9 citations), reducing empiric treatment (3/5 citations), reducing time to diagnosis (2/3 citations), and reducing time to treatment initiation (1/5 citations). CONCLUSIONS: Xpert implementation showed no discernible impact on treatment outcomes compared with conventional smear despite reduced time to diagnosis, time to treatment or reduced level of empiric treatment. Further research is required to learn more about gaps in the existing health system.
Authors: Padmapriya P Banada; Satheesh K Sivasubramani; Robert Blakemore; Catharina Boehme; Mark D Perkins; Kevin Fennelly; David Alland Journal: J Clin Microbiol Date: 2010-08-18 Impact factor: 5.948
Authors: Karen R Steingart; Ian Schiller; David J Horne; Madhukar Pai; Catharina C Boehme; Nandini Dendukuri Journal: Cochrane Database Syst Rev Date: 2014-01-21
Authors: J Creswell; B Rai; R Wali; S Sudrungrot; L M Adhikari; R Pant; S Pyakurel; D Uranw; A J Codlin Journal: Int J Tuberc Lung Dis Date: 2015-05 Impact factor: 2.373
Authors: Danica Helb; Martin Jones; Elizabeth Story; Catharina Boehme; Ellen Wallace; Ken Ho; JoAnn Kop; Michelle R Owens; Richard Rodgers; Padmapriya Banada; Hassan Safi; Robert Blakemore; N T Ngoc Lan; Edward C Jones-López; Michael Levi; Michele Burday; Irene Ayakaka; Roy D Mugerwa; Bill McMillan; Emily Winn-Deen; Lee Christel; Peter Dailey; Mark D Perkins; David H Persing; David Alland Journal: J Clin Microbiol Date: 2009-10-28 Impact factor: 5.948
Authors: Andrew F Auld; Katherine L Fielding; Ankur Gupta-Wright; Stephen D Lawn Journal: Trans R Soc Trop Med Hyg Date: 2016-09-16 Impact factor: 2.184
Authors: S Walusimbi; I Najjingo; S Zawedde-Muyanja; J Musaazi; A Nyombi; W Katagira; J Ssendiwala; W Muttamba Journal: Public Health Action Date: 2022-06-21
Authors: M P Kasaro; O N Chilyabanyama; N S Shah; B Muluka; N Kapata; A Krüüner; I Mwaba; K Kaunda; W L Coggin; X J Wen; G Henostroza; S Reid Journal: Public Health Action Date: 2020-12-21
Authors: Eleanor A Ochodo; Selvan Naidoo; Samuel Schumacher; Karen Steingart; Jon Deeks; Frank Cobelens; Patrick M Bossuyt; Taryn Young; Mark P Nicol Journal: Wellcome Open Res Date: 2019-11-21
Authors: Frederick Haraka; Mwaka Kakolwa; Samuel G Schumacher; Ruvandhi R Nathavitharana; Claudia M Denkinger; Sebastien Gagneux; Klaus Reither; Amanda Ross Journal: Cochrane Database Syst Rev Date: 2021-05-06
Authors: Marcia C B de Oliveira; Clemax C Sant'Anna; Ronir Raggio Luiz; Afrânio L Kritski Journal: Am J Trop Med Hyg Date: 2020-09-17 Impact factor: 3.707